Component composition of body weight in patients with non-alcoholic fatty liver disease
Abstract
The issue of the relationship between the features of the component composition of body weight with the emergence and development of non-alcoholic fatty liver disease (NAFLD) is particularly relevant. The purpose of the study is to determine the features of the component composition of the body weight in patients with NAFLD compared with almost healthy people of the first mature age. A comprehensive examination and analysis of anthropometric data of 112 patients with NAFLD of the first mature age of the Podolski region was carried out in comparison with the anthropometric data of practically healthy people, which were taken from the data bank of the materials of the research center of National Pirogov Memorial Medical University. The necessary anthropometric parameters for determining the absolute amount of adipose tissue, the absolute amount of muscle tissue, the absolute amount of bone component in body weight, using the formulas of J. Matiegka. Statistical analysis of the obtained results was performed in the program “STATISTICA 8” using parametric and non-parametric methods of estimation of the obtained results. It was found that the body fat according to the Matiegka formula in men and women with NAFLD was statistically significantly higher (p<0.001) than in the same sex of healthy men and women. Muscle weight and bone mass calculated by the Matiegka formula in men and women with NAFLD were statistically significantly lower (p<0.05) than in the healthy sex of men and women. Moreover, muscle and bone mass in healthy and NAFLD men were statistically significantly greater (p<0.05) than in the same age groups of women. Men and women with NAFLD have strong inverse correlations between muscle mass and body mass index. Also, the mean strengths of the correlation between the bone mass and body mass index were established. The obtained results, together with a known increase in body fat in NAFLD, show a significant change in muscle and bone mass toward a decrease, which allows us to identify new potential therapeutic targets.
References
[2] Brotto, M., & Bonewald, L. (2015). Bone and muscle: interactions beyond mechanical. Bone, 80, 109-114. doi: 10.1016/j.bone.2015.02.010
[3] Brotto, M., & Johnson, M. L. (2014). Endocrine crosstalk between muscle and bone. Current osteoporosis reports, 12(2), 135-141. doi: 10.1007 / s11914-014-0209-0
[4] Carson, J. A., & Manolagas, S. C. (2015). Effects of sex steroids on bones and muscles: Similarities, parallels, and putative interactions in health and disease. Bone, 80, 67-78. doi: 10.1016/j.bone.2015.04.015.
[5] Dasarathy, S., & Merli, M. (2016). Sarcopenia from mechanism to diagnosis and treatment in liver disease. Journal of hepatology, 65(6), 1232-1244. doi: https://doi.org/10.1016/j.jhep.2016.07.040
[6] Datsenko, G. V., Moroz, L. V., Gunas, I. V., & Dugelny, A. G. (2009). Comprehensive body size in healthy and chronic B and C viral hepatitis patients in urban men and women in Podillya. Biomedical and Biosocial anthropology, 13, 129-134.
[7] Davuluri, G., Krokowski, D., Guan, B. J., Kumar, A., Thapaliya, S., Singh, D., ... & Dasarathy, S. (2016). Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. Journal of hepatology, 65(5), 929-937. doi: 10.1016/j.jhep.2016.06.004
[8] European Association for the Study of the Liver, & European Association for the Study of Diabetes (EASD. (2016). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 64(6), 1388-1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004
[9] Gunas, I. V., Dugelnyi, A. G., Prokopenko, S. V., & Datsenko, G. V. (2009). Somatotype and component composition of body weight in healthy and patients with chronic viral hepatitis “B” or “C” of urban men and women in Podillya. Reports of Morphology, 15(2), 391-396.
[10] Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., ... & Choi, K. M. (2014). Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology, 59(5), 1772-1778. https://doi.org/10.1002/hep.26716
[11] Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., ... & Kim, W. (2017). Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. Journal of hepatology, 66(1), 123-131. doi: 10.1016/j.jhep.2016.08.019.
[12] Koveshnikov, V.G., & Nikityuk, B.A. (1992). Medical anthropology. K.: Health’s.
[13] Kremer, W. M., Koch, S., Lochner, D., Koch, A. C., Hahn, F., Grambihler, A., ... & Weinmann, A. (2019). SAT-067-Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis. Journal of Hepatology, 70(1), e656-e657. doi: https://doi.org/10.1016/S0618-8278(19)31309-X
[14] Lee, Y. H., Jung, K. S., Kim, S. U., Yoon, H. J., Yun, Y. J., Lee, B. W., ... & Cha, B. S. (2015). Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). Journal of hepatology, 63(2), 486-493. doi: https://doi.org/10.1016/j.jhep.2015.02.051
[15] Lim, S., Kim, J. H., Yoon, J. W., Kang, S. M., Choi, S. H., Park, Y. J., ... & Jang, H. C. (2010). Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes care, 33(7), 1652-1654. https://doi.org/10.2337/dc10-0107
[16] Mantovani, A., & Targher, G. (2017). Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Annals of translational medicine, 5(13), 270. doi: 10.21037/atm.2017.04.41
[17] Merli, M., & Dasarathy, S. (2015). Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit? Journal of hepatology, 63(2), 309-311. doi: https://doi.org/10.1016/j.jhep.2015.05.014
[18] Misnikova, I.V., Kovaleva, Yu.A., & Klimina, N.A. (2017). Sarcopenic obesity. Russian Medical Journal, 25(1), 24-29.
[19] Pedersen, B. K., & Febbraio, M. A. (2008). Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiological reviews, 88(4), 1379-1406. doi:10.1152/physrev.90100.2007
[20] Periyalwar, P., & Dasarathy, S. (2012). Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clinics in liver disease, 16(1), 95-131. doi: 10.1016/j.cld.2011.12.009
[21] Piette, A. B., Hamoudi, D., Marcadet, L., Morin, F., Argaw, A., Ward, L., & Frenette, J. (2018). Targeting the muscle-bone unit: filling two needs with one deed in the treatment of Duchenne muscular dystrophy. Current osteoporosis reports, 16(5), 541-553. doi: 10.1007/s11914-018-0468-2
[22] Pivtorak, K. V. (2017). Anthropometric studies of patients with nonalcoholic fatty liver disease. Zaporozhye Medical Journal, 19(5), 623-628. doi: https://doi.org/10.14739/2310-1210.2017.5.110169
[23] Qiu, J., Thapaliya, S., Runkana, A., Yang, Y., Tsien, C., Mohan, M. L., ... & Stark, G. R. (2013). Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB–mediated mechanism. Proceedings of the National Academy of Sciences, 110(45), 18162-18167. https://doi.org/10.1073/pnas.1317049110
[24] Qiu, J., Tsien, C., Thapalaya, S., Narayanan, A., Weihl, C. C., Ching, J. K., ... & McDonald, C. (2012). Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. American Journal of Physiology-Endocrinology and Metabolism, 303(8), E983-E993. doi: 10.1152/ajpendo.00183.2012
[25] Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M. P., Albu, J., ... & Heshka, S. (2004). Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. Journal of applied physiology, 97(6), 2333-2338. doi: 10.1152/japplphysiol.00744.2004
[26] Tandon, P., Ney, M., Irwin, I., Ma, M. M., Gramlich, L., Bain, V. G., ... & Myers, R. P. (2012). Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transplantation, 18(10), 1209-1216. https://doi.org/10.1002/lt.23495
[27] Tovo, C. V., Fernandes, S. A., Buss, C., & de Mattos, A. A. (2017). Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review. World journal of hepatology, 9(6), 326. doi: 10.4254/wjh.v9.i6.326
[28] Tsien, C., Davuluri, G., Singh, D., Allawy, A., Ten Have, G. A., Thapaliya, S., ... & Deutz, N. E. (2015). Metabolic and molecular responses to leucine‐enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology, 61(6), 2018-2029. https://doi.org/10.1002/hep.27717
[29] Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., ... & Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & hepatology, 15(1), 11-20. doi:10.1038/nrgastro.2017.109
[30] Zhai, Y., & Xiao, Q. (2017). The common mechanisms of sarcopenia and NAFLD. BioMed research international, Published online 2017. doi: 10.1155/2017/6297651
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
